All In Biotech

Drug Trial Radar · NCT03470441

A Study of Acute Myocardial Infarction Using FDY-5301

A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction

Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Oct 27, 2017

Primary completion

Jul 14, 2018

Study completion Jan 3, 2019

Sponsor

Lead sponsor
Faraday Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of three dose levels of FDY-5301 compared to placebo in STEMI patients undergoing PCI.

Conditions

  • Acute Myocardial Infarction
  • STEMI

Interventions

  • FDY-5301Drug

    FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.

  • PlaceboOther

    Placebo will be administered intravenously by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arrhythmias of Interest, 48 Hours (Overall)Time frame: First 48 hours post-treatment
  2. Arrhythmias of Interest Incidence Rate, 48 Hours (Overall)Time frame: 48 hours post-treatment
  3. Arrhythmias of Interest, 14 Days (Overall)Time frame: 48 hours to 14 days Post Percutaneous Coronary Intervention (PCI)
  4. Arrhythmias of Interest Incidence Rate, 14 Days (Overall)Time frame: 48 hours to 14 days Post Percutaneous Coronary Intervention (PCI)

Locations

23 sites in 4 countries. Site status is shown where the registry gives one.

  • Minneapolis Heart Institute

    Minneapolis, Minnesota

  • Montefiore Medical Center

    The Bronx, New York

  • Budai Irgalmasrendi Kórház

    Budapest, Hungary

  • Magyar Honvédség Egészségügyi Központ

    Budapest, Hungary

  • Debreceni Egyetem Klinikai Központ, Kardiológiai és Szívsebészeti Klinika

    Debrecen, Hungary

  • Borsod-Abaúj-Zemplén Megyei Központi Kórház

    Miskolc, Hungary

  • Zala Megyei Szent Rafael Kórház

    Zalaegerszeg, Hungary

  • Samodzielny Publiczny Specjalistyczny Szpital Zachodnii im. Jana Pawła II, Oddział Kardiologii Inwazyjnej

    Grodzisk Mazowiecki, Poland

  • Samodzielny Publiczny Specjalistyczny Szpital Zachodnii im. Jana Pawła II, Oddział Kardiologii Inwazyjnej

    Krakow, Poland

  • Klinika Elektrokardiologii; Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi

    Lodz, Poland

  • Miedziowe Centrum Zdrowia

    Lubin, Poland

  • Klinika Kardiologii Inwazyjnej; Centralny Szpital Kliniczny MSWiA w Warszawie

    Warsaw, Poland

  • KLINIKA KARDIOLOGII, 4 Wojskowy Szpital Kliniczny

    Wroclaw, Poland

  • Samodzielny Publiczny Szpital Kliniczny Nr 7 Śląskiego Uniwersytetu Medycznego w Katowicach, Górnośląskie Centrum Medyczne im. Prof. Leszka Kieca., III Oddz. Kardiologii

    Katowice, Silesian Voivodeship, Poland

  • Ninewells Hospital and Medical School

    Dundee, United Kingdom

  • Royal Infirmary of Edinburgh

    Edinburgh, United Kingdom

  • Golden Jubilee National Hospital

    Glasgow, United Kingdom

  • Royal Devon and Exeter Hospital Cardiology Department

    Exeter, Devon, United Kingdom

  • Wythenshawe Hospital

    Manchester, Greater Manchester, United Kingdom

  • Glenfield Hospital

    Leicester, Leicestershire, United Kingdom

  • University of Oxford

    Oxford, Oxfordshire, United Kingdom

  • Freeman Hospital

    Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • New Cross Hospital

    Wolverhampton, West Midlands, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.